Regenerative Medicine Applications
Regenerative medicine therapies have the potential to treat numerous diseases and conditions, such as diabetes, spinal cord injuries and cardiovascular disease, resulting from damaged or failing tissues. In addition, regenerative medicine is desperately needed to help combat rising health care costs.
However, according to the U.S. National Institutes of Health (NIH) and Department of Health and Human Services, progress towards more complex regenerative medicine therapies has been limited due to the inability to observe and understand fundamental tissue interactions in vivo (within the body). Consequently, working with cells that behave in a similar manner outside of the body (in vitro) as they do within it is critically important.
Application of the MLPC
Our first commercial Cell Technologies product is the Multi-Lineage Progenitor Cell™ (MLPC™). This rare stem cell — and its multiple cell lines — is derived from human umbilical cord blood and obtained using PrepaCyte®, BioE's cell separation technology.
The characteristics of our MLPC make it an ideal candidate to overcome some of the current obstacles in regenerative medicine research.
Specifically, the MLPC is a normal, genetically stable, human, non-embryonic stem cell capable of extensive expansion and self-renewal. Our MLPC expands and differentiates outside of the body — in a controllable fashion — into tissues representative of the three germinal layers (e.g., ectoderm, mesoderm and endoderm), including neural stem cells, nerve cells, lung cells, precursor liver and pancreas cells, terminally differentiated liver cells, skeletal muscle, fat cells, bone cells and blood vessels. These MLPC traits help minimize unknown variables when analyzing complex tissue behaviors and interactions.
Furthermore, because our MLPC lines originate from a single cell and not a mixed population of stem cells with an undefined and variable concentration of cells, every duplicate MLPC is an exact genetic copy of its original. This characteristic provides researchers greater control and reproducibility capabilities during research applications.
Additionally, our MLPC is derived from a proven therapeutic source in human umbilical cord blood. Since the late 1980s, cord blood and the stem cells found within it (including the previously unidentified MLPC) have been used to remedy more than 70 genetic diseases, cancers and blood disorders.
The MLPC requires no special culturing conditions for routine maintenance or differentiation, facilitating more efficient use for regenerative medicine research. The ability to retrieve the MLPC from the freezer and controllably differentiate it enables precise, reproducible research today, tomorrow and five years down the line.
For more detailed information about the MLPC, please visit the Products and Support section of our Web site.